Tysabri and PML: Key Differences in Symptoms vs. Diagnosis

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Occupational Exposure Concerns

If you or a loved one is taking Tysabri and experiencing new neurological symptoms, distinguishing between a multiple sclerosis flare and the early signs of progressive multifocal leukoencephalopathy (PML) can be challenging. The medical community has long emphasized the importance of recognizing these differences to guide timely intervention. This guide clarifies the symptoms and diagnostic timeline for PML associated with Tysabri use.

Understanding Tysabri and Its Association with PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Illinois who have developed PML after Tysabri treatment, understanding the medical evidence, risk factors, and legal considerations—including the statute of limitations—is essential. The prescribing information for Tysabri includes a boxed warning stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical data and postmarketing surveillance. PML results from reactivation of the JC virus in immunocompromised individuals, and Tysabri's mechanism—blocking alpha-4 integrin on immune cells—impairs normal immune surveillance of the central nervous system, allowing the virus to proliferate and cause demyelination.

Risk Factors and Clinical Presentation of PML

Three primary risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML. The label advises healthcare professionals to "monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" and to "withhold TYSABRI immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation of PML typically includes progressive neurological deficits such as weakness, visual disturbances, cognitive decline, and coordination problems, which can be mistaken for multiple sclerosis exacerbations. Diagnosis relies on MRI imaging showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid via PCR.

Timeline of Exposure and Harm

The timeline between Tysabri exposure and documented harm varies. PML can occur after a few months to several years of treatment, with risk increasing with cumulative exposure. The label notes that "longer treatment duration, especially beyond 2 years" is a known risk factor (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Once PML develops, outcomes are often poor, with the label stating it "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This underscores the importance of early detection and prompt discontinuation of Tysabri.

Adequacy of Warnings and Legal Considerations

Regarding the adequacy of warnings, the boxed warning and prescribing information clearly communicate the PML risk. However, legal claims may focus on whether these warnings were sufficient to inform patients and healthcare providers of the magnitude of risk, especially given the drug's restricted distribution program called TOUCH, which requires patient enrollment and acknowledgment of risks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Some plaintiffs may argue that the warnings did not adequately emphasize the risk of PML in patients without prior immunosuppressant use or that monitoring recommendations were not sufficiently followed.

Statute of Limitations for Tysabri Claims in Illinois

For settlement-related considerations, affected patients in Illinois must be aware of the statute of limitations for filing a product liability or personal injury lawsuit. In Illinois, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or should have been discovered through reasonable diligence. For PML, this date may be when the diagnosis was confirmed or when symptoms first appeared. Given the latency between Tysabri exposure and PML onset, patients should promptly consult legal counsel to assess their specific timeline. Settlement amounts in Tysabri-related PML cases have historically varied based on factors such as severity of disability, medical expenses, lost wages, and the strength of evidence linking the drug to the injury.

Summary and Recommendations

In summary, Tysabri-associated PML is a serious adverse event with well-defined risk factors and clinical features. Patients in Illinois who develop PML should seek immediate medical evaluation and legal advice to understand their rights and the applicable statute of limitations. The evidence from the prescribing information provides a clear basis for understanding the drug's risks and the need for vigilant monitoring. References - https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Illinois?

In Illinois, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or should have been discovered through reasonable diligence. For PML, this date may be when the diagnosis was confirmed or when symptoms first appeared. It is crucial to consult legal counsel promptly to assess your specific timeline.

What are the primary risk factors for developing PML while on Tysabri?

The three primary risk factors are: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. Patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.